Araştırma özeti
Aşağıdaki metin kaynak makalenin lisansı doğrulanmış orijinal özetidir. cc by
IntroductionPredicting Parkinson's disease (PD) motor progression remains challenging despite advances in neuroimaging. Blood-based transcriptomic profiling offers a more accessible and cost-effective alternative. This study aimed to develop and validate a machine learning approach using blood-based transcriptomic data to predict 12-month motor severity in PD and to identify the transcriptomic features and biological pathways most strongly associated with progression.MethodsA Stacking Regressor ensemble model combining three gradient boosting algorithms (XGBoost, LightGBM, CatBoost) was developed using baseline Parkinson's Progression Markers Initiative (PPMI) data (n = 390), integrating blood RNA sequencing (RNA-seq) and clinical features to predict 12-month UPDRS Part III scores. SHapley Additive exPlanations (SHAP) analysis was applied to identify key prognostic features, evaluating seven PD risk genes (SNCA, LRRK2, GBA, PRKN, PINK1, PARK7, VPS35) and pathway scores for mitochondrial dysfunction, neuroinflammation, and autophagy.ResultsOn an independent test set (n = 78), the model achieved a Coefficient of Determination (R²) of 0.551 and Mean Absolute Error (MAE) of 6.01. SHAP analysis identified the baseline UPDRS × PINK1 interaction (UPDRS_BL × PINK1) as the most influential feature (mean |SHAP| = 0.283). Among transcriptomic features, VPS35 (mean |SHAP| = 0.010), GBA, and LRRK2 were most prominent. Mitochondrial dysfunction showed the highest pathway contribution (mean |SHAP| = 0.008).DiscussionThe study establishes that machine learning integrating blood transcriptomics and clinical data effectively predicts motor progression in PD. Crucially, the interplay between initial clinical state and specific genetic backgrounds-particularly PINK1-is a more powerful prognostic indicator than any factor alone. This study provides systematic evidence that mitochondrial dysfunction is a dominant prognostic signal for disease progression, nominating key genes and pathways for future mechanistic and therapeutic investigation.
Bilimsel değerlendirme
Araştırma sorusu
Sorunun kapsamı orijinal çalışma üzerinden değerlendirilir.
Yöntem ve örneklem
Çalışma tasarımı ve örneklem için kaynak makaleyi kontrol edin.
Temel bulgular
Bu kayıt için editoryal olarak onaylanmış bulgu özeti henüz yayımlanmadı.
Sınırlılıklar
Sonuçların genellenebilirliği, yanlılık ve klinik anlamı ayrıca incelenmelidir.
Bibliyografik veriden yöntem, örneklem veya klinik sonuç çıkarımı yapılmaz.